← Leaderboards
Maria Elena Bottazzi
Baylor College Of Medicine
$5,976,832
Attributed
$14,433,878
Total exposure
5
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.5M · FY2012–24$2.5M$1.9M$1.3M$625K$0
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$14,433,878 · 5
By mechanism
R01$12,354,854 · 2
U19$1,633,070 · 1
R21$440,954 · 1
R13$5,000 · 1
Top collaborators
- Peter J Hotez7 shared
- Shibo Jiang7 shared
- Sara Lustigman5 shared
- Hao Shen5 shared
- Yi-Pin Lin2 shared
Most similar at Baylor College Of Medicine
Same institution · by research overlap
- Sasirekha Ramani$2,951,736
- Richard E Lloyd$10,712,935
- Michael A Helmrath$6,847,164
Others in their field
Top investigators on “Vaccines”
- Lawrence Corey · Fred Hutchinson Cancer Center$829,044,908
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$556,540,832
- Bambra Strokes · Ppd Development Lp$526,656,217
- Barton F Haynes · Duke University$515,215,260
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$398,445,678
- Dennis R. Burton · Scripps Research Institute$316,106,418
Research focus
VaccinesBacteriaProteinsImmunizationIn VivoTechnology TransferVaccine CandidatePre-ClinicalMeetingsInnovationClinical TrialsTimelineCommunicable DiseasesBaseTechnologyToxicologyDisease OutbreaksBuffersFermentationFrontierCyclic GmpClinical LotImmunogenicityNeutralizing Antibody
Grant awards (16)
Regulatory Science Core$1,633,070
U19 · FY2024 · AI · contact PI
Identification of the mechanism of protection against a B. burgdorferi protein CspZ for the prevention of Lyme disease$199,455
R21 · FY2021 · AI
Identification of the mechanism of protection against a B. burgdorferi protein CspZ for the prevention of Lyme disease$241,499
R21 · FY2020 · AI
2019 Tropical Infectious Diseases$5,000
R13 · FY2019 · AI · contact PI
Development of a novel adjuvant for vaccine sparing$1,248,398
R01 · FY2017 · AI
Development of a novel adjuvant for vaccine sparing$1,250,865
R01 · FY2016 · AI
RBD recombinant protein-based SARS vaccine for biodefense$1,165,855
R01 · FY2016 · AI
Development of a novel adjuvant for vaccine sparing$1,197,649
R01 · FY2015 · AI
RBD recombinant protein-based SARS vaccine for biodefense$1,165,726
R01 · FY2015 · AI
Development of a novel adjuvant for vaccine sparing$1,203,147
R01 · FY2014 · AI
RBD recombinant protein-based SARS vaccine for biodefense$1,134,359
R01 · FY2014 · AI
RBD recombinant protein-based SARS vaccine for biodefense$3,936
R01 · FY2014 · AI
Development of a novel adjuvant for vaccine sparing$1,393,822
R01 · FY2013 · AI
RBD recombinant protein-based SARS vaccine for biodefense$1,085,321
R01 · FY2013 · AI
RBD recombinant protein-based SARS vaccine for biodefense$3,936
R01 · FY2013 · AI
RBD recombinant protein-based SARS vaccine for biodefense$1,501,840
R01 · FY2012 · AI